Company Overview
Liminatus Pharma, Inc. operates as a pre-clinical stage biopharmaceutical entity dedicated to the development of novel cancer therapies, specifically focusing on the creation of a high affinity humanized anti CD47 antibody. This antibody is designed to facilitate CD47 SIRPa blocking and restore the anti-tumor function, positioning the company within the specialized landscape of oncology research. The firm functions within the Healthcare sector and the Biotechnology industry, classifications that define its reliance on scientific innovation and regulatory pathways rather than immediate commercial product sales. The company's scale is defined by a market capitalization of $7.38M, with reported annual revenue of N/A and an employee count listed as N/A. These valuation and revenue figures indicate that Liminatus Pharma is a micro-cap entity in the early developmental phase, where value is derived from intellectual property and clinical potential rather than established cash-generating operations or significant workforce deployment.
Financial Health
The company reports revenue of N/A for the trailing twelve months, with a net income of $-2,267,033 and an EBITDA of N/A. The significant negative net income relative to the absence of reported revenue highlights a cost structure dominated by research and development expenditures typical of pre-clinical biotechnology firms, where operational expenses exceed any current revenue generation. Free cash flow stands at $-676,760, indicating that the company is consuming cash reserves to fund its operations and development pipeline, which limits immediate financial flexibility but is characteristic of the industry stage. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, a figure that reflects the lack of commercial revenue against which margins are calculated, rather than operational inefficiency. The company holds cash of $724,502 against a total debt load of $1.44M, resulting in a debt-to-equity ratio of N/A. This balance sheet configuration suggests a leveraged position relative to cash on hand, as total debt exceeds available liquid assets, though the debt nature is likely structured to support long-term development rather than short-term obligations. The current ratio is 0.42, which indicates that the company possesses less than half the liquid assets required to cover its current liabilities, signaling constrained short-term liquidity that necessitates continuous capital infusion. Return on Equity is listed as N/A due to the absence of positive net income, while return on assets stands at -48.1%, revealing that the company's asset base is generating negative returns on an annualized basis. These return metrics collectively underscore the high-risk nature of the investment, where management effectiveness is measured by the ability to preserve value rather than generate profit.
Valuation Assessment
The trailing P/E ratio is N/A and the forward P/E ratio is also N/A, a status that implies earnings are currently negative and traditional valuation multiples based on profitability are not applicable. The price-to-book ratio is -3.07, a negative figure that indicates the market capitalizes the company at a value significantly below its book value, reflecting the high risk associated with pre-clinical assets that have not yet reached commercialization. The price-to-sales ratio and EV/EBITDA are both N/A, suggesting that alternative valuation metrics relying on revenue multiples or enterprise value are not currently calculable or meaningful given the company's financial profile. The stock has traded between a 52-week high of $33.66 and a 52-week low of $0.18, illustrating extreme volatility and a wide trading range typical of small-cap biotech stocks. The beta value is 0.50, which indicates that the stock's price volatility is historically lower than that of the broader market, suggesting less sensitivity to general market movements despite its high idiosyncratic risk.
Growth & Income
Revenue growth year-over-year is N/A and earnings growth year-over-year is N/A, precluding any analysis of whether earnings are growing faster or slower than revenue at this stage of the company's lifecycle. As the company does not pay a dividend, there is no dividend yield or payout ratio to report, and consequently, the payout ratio is 0.0%. This non-dividend status confirms that the company retains all earnings and cash flow to reinvest into its research and development efforts rather than distributing income to shareholders. The overall growth and income profile is characterized by the absence of historical growth rates and a complete lack of dividend distribution, focusing entirely on capital appreciation potential through future clinical milestones.